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Abstract
Varicella zoster virus (VZV) is a leading cause of acute viral encephalitis but little is known about its clinical, biological and imaging fea-
tures. Furthermore, the most favourable treatment regimen has not been determined. We studied a prospective cohort of 20 HIV-neg-
ative patients presenting with acute VZV encephalitis caused by primary infection or reactivation. VZV was identified in 16 of 20 cases
by PCR detection of the DNA in the cerebrospinal fluid. The four remaining cases occurred during or soon after a VZV rash. The med-
ian age of the 17 adults was 76 (19–86) years; the three other patients were children (0.5–5 years). Three patients were immunocom-
promised. Nine adult patients presented with a rash. Eighteen patients presented with fever and an acute encephalitic syndrome: diffuse
brain dysfunction, focal neurological signs, seizures and cranial nerve palsies. Three patients presented with either ventricular or sub-
dural haemorrhage, one with myelitis, and one with asymptomatic stenosis of the middle cerebral artery. The imaging was either normal
or revealed non-specific abnormalities such as cortical atrophy but no evidence of stroke. All patients were given acyclovir at various
dosages and durations but the case fatality rate remained high (15%) and sequelae were frequently observed either at discharge or at
follow-up 3 years later.
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Introduction
Varicella zoster virus (VZV) is a virus of the Alphaherpesviri-
nae subfamily, responsible for human infections with various
clinical presentations. Primary infection occurs most fre-
quently during childhood and presents as varicella; it is fol-
lowed by long-lasting viral latency in the spinal and cranial
ganglia [1,2]. This infection is common, affecting almost all
non-vaccinated children. Infection reactivation occurs mainly
in immunocompromised or elderly patients. The most fre-
quent presentation in adults is herpes zoster (shingles), with
an estimated annual incidence of 1.2–5.2 cases/1000 [2].
Post-herpetic neuralgia is a frequent complication in elderly
patients [3].
Neurological complications caused by varicella can involve
peripheral or central nervous system. They include cerebelli-
tis, meningitis, myelitis, optic neuritis, polyneuropathy, acute
encephalitis and vasculopathy [2,4]. Some neurological pre-
sentations can also appear with, precede, or follow herpes
zoster: sensory or motor peripheral paralysis, isolated and
multiple cranial nerve palsies including ophthalmoplegia and
the Ramsay Hunt syndrome, myelitis, encephalitis, vasculopa-
thy and cerebellar ataxia [5]. Neurological symptoms caused
by VZV infection can also occur without any cutaneous rash
(zoster sine herpete) and the detection of DNA or specific
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VZV antibodies in the cerebrospinal fluid (CSF) is here the
only proof of VZV involvement [5].
Several mechanisms explain the occurrence of neurological
signs after VZV infection: parenchymatous encephalitis (with
or without demyelination), microglial influx, granulomatous
and large vessel vasculopathy inducing strokes (grossly tran-
sient cerebral arteriopathy in children and delayed contralat-
eral hemiparesis of zoster ophthalmicus in the elderly),
meningitis or necrotizing myelitis [6,7]. Subacute or chronic
VZV encephalitis are encountered in immunocompromised
patients as the result of small vessel vasculopathy and glial
infection inducing leukoencephalitis. Myelitis, large vessel
involvement and ventriculitis have also been reported [7,8].
Acute ataxia in children and vasculopathies in adults are the
most frequently cited neurological complications of VZV
infection [5,9,10]. In contrast, acute encephalitis sensu stricto
has rarely been reported [11–14] and even fewer reports
have been published describing the clinical features and fol-
low-up of these patients [15–18]. The importance of VZV in
the epidemiology of acute encephalitis in the general popula-
tion has been highlighted in multicentre prospective studies
[11–13].
We report the clinical features of patients with VZV
encephalitis enrolled in a prospective multicentre study in
France, in 2007.
Methods
A case-patient with acute encephalitis was a patient 28 days
of age or older hospitalized in mainland France in 2007, with
(i) an acute onset of illness; (ii) at least one abnormality of
CSF (white blood cell count ‡4 cells/mm3 or protein level
‡40 mg/dL); (iii) fever or recent history of fever ‡38C; and
(iv) decreased consciousness, or seizures, or altered mental
status, or focal neurological signs. HIV infection was an
exclusion criterion. Aetiological investigation of enrolled
patients was described previously [11].
A confirmed case of VZV encephalitis was a case-patient
with VZV DNA detected in the CSF by PCR. A possible
case of VZV encephalitis was a case-patient with encephali-
tis occurring simultaneously or shortly after varicella or
herpes zoster without biological confirmation of VZV infec-
tion, and with other possible aetiologies of encephalitis
excluded by the investigation. Clinical and biological data
were collected using a standardized questionnaire and the
results of electroencephalography examinations were
recorded. A single expert (TdB) reviewed all available mag-
netic resonance and computed tomography images to assess
brain lesions.
The outcome of VZV patients was assessed 3 years after
discharge using the Glasgow outcome scale [19].
Informed written consent was obtained from all patients
or from their parents for children aged <18 years. The study
was approved by the ethics committee of Grenoble (No.
172003).
Results
Demography
Twenty of 253 (8%) case-patients enrolled in the initial study
were VZV patients [11]. Sixteen were confirmed cases and
four were possible cases (Table 1). Two possible cases were
5-year-old boys with negative VZV CSF PCR on admission
and no further CSF testing. They presented with varicella,
respectively, 1 day and 1 week before the onset of neurolog-
ical symptoms. The two other possible cases were adults (76
and 78 years of age) presenting with radicular zoster (one
spinal, one ophthalmicus) 3 days and 3 weeks, respectively,
before the onset of neurological symptoms.
The male to female ratio was 3. Three patients were chil-
dren (the two 5-year-old boys mentioned above and a 6-
month old boy). The distribution of age among adult patients
was bimodal with three young adults (19, 20 and 26 years
old) and 11 people ‡75 years old (median 76 years old,
range 19–86 years). None of the VZV patients had ever been
vaccinated against VZV.
Clinical features
Ten (50%) patients (nine adults and one child) had comorbid-
ities, three of which could be considered immunosuppressive
conditions: osteosarcoma, recent heart–lung transplant and
systemic lupus erythematosus with long-term corticosteroid
treatment (Table 1).
Eleven VZV patients (55%) had a rash before hospitaliza-
tion: zoster in eight adults and varicella in three children, of
whom two (a child and an adult) no longer had cutaneous
signs on admission.
The symptoms of the VZV patients on admission are pre-
sented by frequency in Table 2. Six patients (30%) required
admission to intensive care units, four were mechanically
ventilated. The most frequent neurological symptoms were
disorientation and confusion (70%), meningeal signs (60%),
focal neurological signs (55%) and apathy (50%). Cranial
nerve palsy was present in eight patients (40%), namely cen-
tral facial nerve paralysis in seven cases and oculomotor
nerve paralysis in one case.
Lumbar puncture was performed before day 2 of hospi-
talization in 80% of cases and before day 4 in 95%. The
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median CSF white blood cell count was 150 cells/mm3
(range 0–1240). Lymphocytes were predominant in CSF
(median rate: 81.5% of white blood cells) in all but two
VZV patients. The median protein level in CSF was 0.99 g/L
(0.22–5 g/L). The glucose CSF/serum ratio was >0.40 in 16
patients (80%).
Thirteen of 14 (92%) encephalography recordings showed
abnormalities and all such abnormalities were consistent with
diffuse brain lesions. Focal temporal slow waves were identi-
fied in four cases, and subclinical seizures in two cases.
Imaging
All patients underwent computed tomography scan (n = 10),
magnetic resonance imaging (n = 2), or both (n = 8) on
admission. Eighteen sets of images were available for review-
ing (14 confirmed cases and four possible cases). Four (20%)
patients demonstrated vascular lesions on computed tomog-
raphy of magnetic resonance imaging:
• stenosis of the left middle cerebral artery M1 segment
was observed using magnetic resonance angiography in a
20-year-old patient without stroke (Fig. 1);
• a 6-month-old boy presented with diffuse bleeding and
dilatation of the ventricles on admission and still had a
dilatation of the subarachnoid area with normal ventricu-
lar size on follow-up imaging (Fig. 2);
• thoracic myelitis was observed on admission in a 34-
year-old man with paraplegia, who developed at day 45 a
bilateral subdural haematoma and massive ventricular
bleeding (Fig. 3);
• a 79-year-old patient with cortical atrophy on early
images later demonstrated a haematoma in the thalamic
area with fatal ventricular bleeding at day 23.
Three (15%) other patients had non-vascular lesions: brain-
stem lesions suggesting rhombencephalitis were observed in
two patients; and right-side temporal, parietal and occipital
hypersignals were observed with magnetic resonance imaging
in a 5-year-old boy (possible case).
Four patients (20%), including one possible case, had non-
specific abnormalities (cortical atrophy) and the remaining
FIG. 1. Magnetic resonance image of a 20-year-old man. Narrowing
of the M1 segment of the middle cerebral artery.
TABLE 2. Clinical features of 20 patients presenting with varicella zoster virus encephalitis at day 0 and day 5
Day 0 Day 5
All cases
(n = 20)
Confirmed cases
(n = 16)
Possible cases
(n = 4)
All cases
(n = 20)
Confirmed cases
(n = 16)
Possible cases
(n = 4)
Fever 18 (90%)a 15 (94%)b 3 (75%)b NA NA NA
Mechanical ventilation 4 (20%) 1 (6%) 3 (75%) 3 (15%) 1 (6%) 2 (50%)
Severe sepsis 1 (5%) 1 (6%) 0 0 0 0
Meningism 12 (60%) 9 (56%) 3 (75%) 3 (15%) 3 (19%) 0
Decreased level of consciousness 5 (25%) 3 (19%) 2 (50%) 2 (10%) 1 (6%) 1 (25%)
Disorientation 14 (70%) 11 (69%) 3 (75%) 5 (25%) 5 (31%) 0
Confusion 14 (70%) 12 (75%) 2 (50%) 2 (10%) 2 (13%) 0
Seizures 4 (20%) 2 (13%) 2 (50%) 0 0 0
Focal neurological signs 11 (55%) 7 (44%) 4 (100%) 9 (45%) 7 (44%) 2 (50%)
Speech disorders 6 (30%) 5 (31%) 1 (25%) 2 (10%) 1 (6%) 1 (25%)
Cranial nerve palsy 8 (40%) 6 (38%) 2 (50%) 8 (40%) 6 (38%) 2 (50%)
Cerebellous syndrome 3 (15%) 2 (13%) 1 (25%) 3 (15%) 2 (13%)
Sensory disorders 1 (5%) 1 (6%) 0 NA NA NA
Myelitis 0 0 0 1 (5%) 1 (6%) 1 (25%)
Aggressiveness 1 (5%) 1 (7%) 0 0 0 0
Apathy 10 (50%) 7 (44%) 3 (75%) 3 (15%) 3 (19%) 0
Agitation 6 (30%) 4 (27%) 2 (50%) 1 (5%) 1 (6%) 0
Parkinsonism 0 0 0 NA NA NA
Movement disorders 0 0 0 0 0 0
Hallucination 0 0 0 0 0 0
NA, not available.
aTwo patients were afebrile while taking antipyretic treatment but reported fever before hospitalization.
bOne patient was afebrile while taking antipyretic treatment but reported fever before hospitalization.
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seven (35%) patients, including two possible cases, had nor-
mal imaging results. Ischaemic stroke was ruled out by imag-
ing in all patients.
Treatment
Five of the eight adult patients with zoster rash received acy-
clovir before the onset of neurological symptoms. Acyclovir
was administered intravenously to all 20 patients as encepha-
litis treatment for 3 weeks (n = 8; 40%), 2 weeks (n = 5;
25%) or 1 week (n = 7; 35%). Dosage was reported for 13
of 20 patients: five received 10 mg/kg three times a day, six
received 15 mg/kg three times a day and two children
received 20 mg/kg three times a day.
Outcome
Three male VZV patients (15%) died during hospitalization:
all three were elderly (75, 79 and 82 years old). The mean
duration of hospital stay was 23 days (range 6–80). On dis-
charge, 10 patients (50%) returned home, six patients (30%)
were transferred to a convalescence facility, and one moved
to a nursing home.
Nine patients (45%) were discharged with persistent neu-
rological signs: cognitive impairment (n = 3) and sensory-
motor deficits (n = 6). Three years after discharge, 16 of the
17 surviving patients could be evaluated and one was lost to
follow-up. Among the 16 patients, two had died after being
discharged (with one death being related to the encephalitis),
seven (41%) had moderate to severe sequelae (Glasgow out-
come scale 3 or 4), and the outcome was favourable for
seven (41%) with a Glasgow outcome scale of 5.
Discussion
Varicella zoster virus has been confirmed as a major cause
of encephalitis in France both in the national hospital data-
base and a prospective cohort study [11,20], as well as in
other countries [12,13].
The data described here highlight the main clinical features
of VZV encephalitis. VZV encephalitis is a disease of the
young and elderly immunocompetent patients, as well as a
disease of the immunocompromised of all ages, as illustrated
by four young adults enrolled in our study.
Varicella zoster virus encephalitis has been described dur-
ing the course of or after varicella or zoster with various
time frames. However, the rash was absent in nine of 17
adult patients enrolled in our study with clinical encephalitis
and a positive VZV PCR in CSF. Conversely, no virological
(a) (b)
(c) (d)
FIG. 2. Magnetic resonance image of a 6-
month-old boy. (a, b) Axial T2 gradient echo
sequence: blood in the ventricles and internal
and external hydrocephaly. (c) Axial SET1
sequence after gadolinium infusion: no abnor-
mal enhancement. (d) FLAIR sequence: no
parenchymal abnormality.
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confirmation could be obtained in four patients whose
encephalitis occurred during or shortly after varicella or zos-
ter. In these four patients, the clinical signs, imaging and out-
come strongly suggested a causative link between VZV and
the encephalitis, and the negative result of the PCR might be
related to the early CSF sampling, or to the administration
of acyclovir before CSF sampling [17,21]. The possible lack
of sensitivity of the PCR has been demonstrated for herpes
simplex virus during the first days of neurological signs but
not formally for VZV. In these four patients, it may have
been interesting to have VZV antibodies measured in a con-
valescent sample of CSF to try to confirm the diagnosis [21].
Few studies have been published about patient with VZV
encephalitis (Table 3). In a paediatric study, the case-fatality
rate among encephalitis patients was 34%, which is higher
than in our patients but this study was published before
molecular diagnosis and acyclovir were available [15]. In a
12-patient cohort reported in 1983, ten patients had their
neurological onset a mean of 9 days after a zoster rash and
two patients reported no rash, which is comparable to our
study [16]. Their case fatality rate was 25%, but there again
the study was carried out before acyclovir was widely avail-
able. In a more recent study, CSF samples from encephalitis
patients were screened for VZV and seven patients were
diagnosed with VZV encephalitis during a 5-year period.
Their demographic characteristics (especially the bimodal dis-
tribution of age), and their clinical signs were similar to those
observed in our prospective study [18].
Twenty-six patients with positive CSF VZV DNA were
referred to the California Encephalitis Project, 11 suffering
encephalitis [30]. Some features were similar to those of our
patients (median age 75 years, 73% of imaging was normal or
non-specific), although a zoster rash was more frequent
(64%).
Varicella zoster virus encephalitis is known to be associ-
ated with immunosuppression, especially that caused by HIV.
Because HIV infection was an exclusion criterion, it is likely
that we missed some patients with VZV encephalitis and HIV
infection. However, the case reports published about VZV
encephalitis in patients with AIDS show that their clinical
presentation does not differ from that of immunocompro-
mised patients following cancer or long-term immunosup-
pressive treatment.
No study or clinical trial has yet addressed the best thera-
peutic regimen for VZV encephalitis. The prognosis of her-
pes simplex virus encephalitis has been dramatically
improved by the use of acyclovir and this treatment is rec-
ommended in the guidelines for VZV encephalitis [2]. The
recommended regimen is acyclovir at the same dosage as
herpes simplex virus encephalitis treatment despite the lack
of paediatric data [14,31,32]. Unlike herpes simplex virus,
few studies have been published on VZV encephalitis [33]. In
(a) (b)
(c) (d)
FIG. 3. Magnetic resonance image of a
35-year-old man. (a–c) Cranial magnetic
resonance image, FLAIR sequence showing
punctiform hyperintensities subcortical (right
frontal and left temporal) and in the pons.
(d) Sagittal dorsal spinal cord, T2 sequence:
hypersignal at the T7–T8 level.
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our study, 3 years after discharge, half of the survivors still
presented with moderate to severe sequelae. Some authors
have suggested that the combination of acyclovir and foscar-
net might improve the prognosis and also prevent a possible
antiviral failure caused by an acyclovir-resistant VZV strain,
but this hypothesis has yet to be confirmed by clinical trial
[34].
Questions and controversies remain on the physiological
mechanisms of the neurological complications of VZV infec-
tion. These complications are different during primary infec-
tion (varicella) and after viral reactivation (zoster). The most
frequent varicella complications are cerebellitis and arterial
ischaemic strokes [15,35,36]. Usually, VZV cerebellitis or
ataxia has a favourable outcome in children and CSF analysis
is generally not performed in this context. Besides ataxia,
arterial ischaemic stroke occurs in up to 1/15 000 cases
[36]. This syndrome, now referred to as post-varicella arteri-
opathy, is defined by focal stenosis of the basal central arter-
ies in children with a history of varicella within the
12 months before the onset of neurological signs.
Varicella acute encephalopathy with fatal outcome has also
been reported following varicella in children with liver and
brain oedema and fatty macrophage infiltration as the result
of Reye’s syndrome, although this does not actually corre-
spond to a direct invasion of the central nervous system
[15].
The physiopathology of VZV encephalitis after reactivation
of the virus is still not clear. The presentations of herpes
zoster encephalitis can be divided into three main categories:
demyelinating disease, vasculopathy and acute infectious
encephalitis of undetermined pathophysiology, as reported in
this case series. The multifocal subacute demyelinating dis-
ease is mostly encountered in immunosuppressed patients,
especially those with AIDS (which was an exclusion criterion
in our study). The direct infection of glial cells and endothe-
lial vascular cells has been demonstrated in these cases [7].
The VZV-induced vasculopathy occurs in immunocompetent
elderly people or in AIDS patients (for instance, zoster oph-
thalmicus contralateral syndrome) [8,29]. Although some
authors claim that most, if not all, cases of herpes zoster
‘encephalitis’ are the result of viral vasculopathy [5,9], imag-
ing failed to demonstrate either vascular lesions or demyelin-
ating areas in 16 of 20 patients enrolled in our study, which
is in favour of direct viral parenchymatous encephalitis.
However, one patient in our series presented with both
myelitis and vasculopathy. He was under immunosuppressive
treatment following heart and lung transplant, and suffered
renal deficiency and diabetes. Myelitis has been described as
a non-vascular clinical presentation, and it has been hypothe-
sized that long-term steroids might be a risk factor for VZV
myelitis [1]. The clinical features and imaging results in this
patient suggest the simultaneous occurrence of two different
clinical presentations: first the myelitis, and second the vas-
culopathy. We can hypothesize that the immunosuppressive
condition of this patient favoured the persistence of a high
viral load in the brain arteries, leading to a massive vasculop-
athy both in subdural and ventricular areas.
Unlike herpes simplex virus, the correlation between the
presence of VZV in CSF and brain infection has not been
demonstrated. However, it has been demonstrated that the
VZV viral load in the CSF was correlated to the severity of
central nervous system symptoms in patients presenting with
encephalitis [37]. Moreover, the acyclovir-induced clearance
of VZV DNA from the CSF was associated with clinical
improvement in four cases of encephalitis [26]. These find-
ings are in favour of a direct viral encephalitis besides vascu-
laritis and demyelinating encephalitis. However, some
crossover between acute VZV encephalitis and VZV-induced
vasculopathy cannot be excluded, and both mechanisms
might exist in the same patients following reactivation of the
virus. This is suggested by the observation of a patient
enrolled in our study with a large vessel vasculopathy on
angiography and normal brain imaging excluding both a
stroke and a demyelinating process.
Conclusion
Varicella zoster virus encephalitis is the second leading cause
of acute infectious encephalitis in France, accounting for
nearly 10% of all cases. According to our results, this diagno-
sis should be considered in any case of central nervous sys-
tem acute febrile disease with lymphocytic aseptic meningitis,
especially in elderly and immunocompromised patients. The
absence of any rash, as in more than half of the cases in our
study, should not be considered as evidence excluding the
diagnosis of VZV encephalitis. Despite the low level of evi-
dence, acyclovir treatment should be prescribed to these
patients, because of its antiviral effectiveness against VZV.
The case fatality rate remains high and sequelae are frequent.
Controversies remain about its pathophysiology and further
research should be undertaken to determine the optimal
therapeutic regimen.
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